Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06996600 · ClinicalTrials.gov registry record · NA

Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device

A NA study of Hydrocephalus, sponsored by Rhaeos.

Recruiting
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT06996600 is a NA study of Hydrocephalus that is actively recruiting participants, run by Rhaeos. The registered enrollment target is 29 participants, below the 132-participant average among 17 other Hydrocephalus trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06996600, a NA study of Hydrocephalus, is actively recruiting participants, sponsored by Rhaeos.

RECRUITING
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.

Conditions Studied

Interventions

  • DEVICE wireless thermal anisotropy measurement device

Study Locations (1)

Illinois

  • Rhaeos, Inc - Chicago

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2025-05-02
Est. Completion 2025-12
Phase NA

Sponsor

Rhaeos

15 total trials

What the Registry Record Tells You About NCT06996600

The ClinicalTrials.gov registry entry for NCT06996600 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 17 other Hydrocephalus trials with a reported enrollment target (78% lower). The listed sponsor is Rhaeos, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which wireless thermal anisotropy measurement device is the first listed.

NCT06996600 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06996600 about?

NCT06996600 is a clinical study titled "Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device". This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow over multiple measurements performed by a study subject during headache and non-headache periods.

What is the current status of trial NCT06996600?

This trial is currently recruiting. It is a NA study. The enrollment target is 29 participants. The study started on 2025-05-02. Estimated completion is 2025-12.

What conditions does trial NCT06996600 study?

This clinical trial studies the following conditions: Hydrocephalus.

What interventions are being tested in trial NCT06996600?

The interventions under investigation include: wireless thermal anisotropy measurement device (DEVICE).

Who is sponsoring clinical trial NCT06996600?

This trial is sponsored by Rhaeos, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06996600 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hydrocephalus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.